



# Profectus Biosciences



**Contact:** Jeffrey Meshulam    **Location:** Baltimore, MD    **Email:** [meshulam@profectusbiosciences.com](mailto:meshulam@profectusbiosciences.com)    **Tel:** 443-743-1107    **Website:** [www.profectusbiosciences.com](http://www.profectusbiosciences.com)



## Company Profile

**Industry Sector:** Biotechnology, Prophylactic & Therapeutic Vaccines

**Company Overview:** Profectus BioSciences, Inc. is a clinical-stage biotechnology company pioneering a major evolutionary step in the design and development of preventive and therapeutic vaccines. Our approach is based on the flexible Prime/Boost System of Vaccination (PBS Vax™) that provides the ability to “tune” the immune response for a specific target and disease context.

**Target Market(s):** The company develops vaccines for markets with significant commercial potential as well as those intended for emergency use or to have a significant global health impact. This opportunity is a therapeutic vaccine for HSV-2 infection.



## Key Value Drivers

**Technology\*:** The PBS Vax™ system comprises of VesiculoVax™ vaccines, replication-competent vesiculoviruses and combinations of DNA and genetic adjuvants that program a protective immune profile specific for the target pathogen.

**Competitive Advantage:** The surface of HSV can have up to 13 glycoproteins that mediate entry and cell-to-cell spread. While other HSV vaccines only target one or two of these glycoproteins, the Company is expressing multiple glycoproteins in its PBS Vax™ system to push the immune system to disrupt these complex entangled structures as they appear on the virus.

**Plan & Strategy:** The Company is seeking to raise \$10.5M to finance the development of the HSV-2 vaccine. The Company intends to pursue the therapeutic vaccine first since the clinical trials will be smaller and less expensive, thus facilitating a quicker route to market.



## Management

**Leadership:** A seasoned vaccine development team with members from big pharma, whose expertise covers all aspects of vaccine development with proven skills necessary to create new vaccines that will have a significant impact for patients worldwide.

Jeffrey Meshulam, President  
John Eldridge, Ph.D., Chief Scientific Officer



## Product Pipeline

Assuming capital is raised in Q2 2016

Milestone	Cost (\$M)	2016				2017				2018				2019			
		Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	
Build vaccine, Complete preclinical animal studies	\$1.4																
cGMP Manufacture, release PBS Vax™-HSV-2, Complete Preclinical Safety	\$7.5																
File IND, Execute Phase 1 Clinical Trial	\$1.7																

Exit with potential upside \$80M through acquisition of product by large pharma/biotech interest